Invitae Corporation
NVTA
株式のランク
#35757
Invitae Corporation operates as a medical genetics enterprise, striving to... Invitae Corporation operates as a medical genetics enterprise, striving to integrate genetic insights into mainstream medical practice to enhance healthcare outcomes for individuals in the United States, Canada, and internationally. The company provides a comprehensive suite of offerings, including genetic testing for various clinical specializations such as hereditary cancer, cardiovascular health, neurological disorders, pediatric conditions, oncology, metabolic ailments, and rare diseases, alongside digital health tools and health data services. Its clientele spans individual patients, healthcare providers, biopharmaceutical firms, and other collaborators. Established in 2010 as Locus Development, Inc., the company officially became Invitae Corporation in 2012 and is headquartered in San Francisco, California.
株価
$0.016
最終同期: 2024-03-11
時価総額
$3.27M
変化（1日）
-5.33%
変化（1年）
5,233.33%
国
US
取引 Invitae Corporation (NVTA)
カテゴリー
Healthcare
Invitae Corporation（NVTA）の収益
Sep 2023 時点の収益 TTM: $481.58M
Invitae Corporation の最新の財務報告によると、現在の収益 (TTM) は $481.58M です。2022 年には $516.30M の収益があり、これは 2021 年の $460.45M と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Invitae Corporation の収益履歴（2016 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $481.58M | -1.11% |
| 2023 | $487.00M | -5.68% |
| 2022 | $516.30M | 12.13% |
| 2021 | $460.45M | 64.68% |
| 2020 | $279.60M | 28.95% |
| 2019 | $216.82M | 46.80% |
| 2018 | $147.70M | 116.50% |
| 2017 | $68.22M | 172.36% |
| 2016 | $25.05M | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $46.34B | 9,521.60% |
US
|
|
| $25.11B | 5,113.43% |
US
|
|
| $2.71B | 462.12% |
US
|
|
| - | - |
CN
|
|
| $7.37B | 1,430.78% |
US
|
